Accendra Health Confirms FY26 Guidance for Net Revenue and Adjusted EBITDA
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 11 2026
0mins
Accendra Health backs FY26 guidance for net revenue and adjusted EBITDA
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ACH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ACH
Wall Street analysts forecast ACH stock price to rise
3 Analyst Rating
1 Buy
1 Hold
1 Sell
Hold
Current: 3.210
Low
2.50
Averages
3.50
High
4.00
Current: 3.210
Low
2.50
Averages
3.50
High
4.00
About ACH
Accendra Health, Inc., formerly Owens & Minor, Inc., is a provider of products, technology, and services for health beyond the hospital for millions of people each year. The Company connects patients, providers, and insurers, delivering solutions for people living with chronic, complex health conditions. It provides delivery of products, including disposable medical supplies sold directly to patients and home health agencies and is a provider of integrated home healthcare equipment and related services in the United States. It offers a range of products and services for in-home care and delivery across diabetes treatment, home respiratory therapy (including home oxygen and non-invasive ventilation services), and obstructive sleep apnea treatment (including continuous positive airway pressure (CPAP) and bi-level positive airway pressure devices, and patient support services). The Company also provides clinical and administrative support services and related products and supplies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Accendra Health Announces Early Results of Bond Exchange Offers
- Successful Bond Exchange Offers: As of June 9, 2026, Accendra Health received valid tenders for approximately $478.3 million of 2029 Notes and $547.9 million of 2030 Notes, representing 99.9% and 99.2% of the total amounts, respectively, indicating strong investor interest in the new bond issuance and enhancing the company's capital structure.
- New Bond Issuance Plan: The company plans to issue $326.25 million in aggregate principal amount of newly issued First Lien Notes, aimed at optimizing its financial condition through the introduction of new funds, which is expected to enhance the company's financial flexibility and market competitiveness.
- Amendment of Covenant Terms: The company has obtained the necessary consents from existing bondholders to amend covenant terms to eliminate most restrictive clauses, which will facilitate greater flexibility in future mergers and financing activities, further driving business growth.
- Timeline Adjustments: The expected early settlement date for all existing notes is set for June 15, 2026, with the expiration time for the exchange offers extended to June 23, 2026, providing investors with more opportunities to participate and potentially increasing the liquidity of the bonds.
See More
Accendra Health Launches Bond Exchange Offers
- Exchange Offer Initiation: Accendra Health has announced the commencement of exchange offers for its 4.500% and 6.625% Senior Notes, aiming to replace existing notes with newly issued 9.000% and 9.750% Senior Secured Notes, thereby optimizing its capital structure and reducing financing costs.
- New Money Notes Issuance: The company is offering $326.25 million in new money notes to incentivize existing noteholders to participate, which is expected to enhance liquidity and support future financial flexibility.
- Covenant Amendments: The company is soliciting significant amendments to the existing notes' covenants, including the elimination of most affirmative and negative covenants, which will help improve operational flexibility and reduce compliance costs.
- Commitment Agreement Support: The company has entered into a commitment agreement with existing noteholders, with approximately 83% of 2030 noteholders expected to participate, indicating strong market confidence in the company's strategic direction.
See More
Accendra Health Earnings Review: Revenue Decline and Debt Management
- Revenue Decline: Accendra Health reported a 6.8% revenue decline in Q1, primarily due to exiting a large commercial payor, with an estimated growth of about 1% if this impact is excluded, posing challenges to the company's future revenue stability.
- Adjusted EBITDA: The company achieved an adjusted EBITDA of $58 million, in line with expectations, indicating a relative stability in operational efficiency despite revenue pressures, reflecting its ability to maintain profitability.
- Debt Management Plan: The company anticipates deleveraging up to $115 million through exchange offers for new notes, although it faces an estimated annual interest expense increase of about $40 million, which will negatively impact free cash flow.
- Market Performance: Despite overall revenue decline, the sleep category achieved over 4% growth, indicating strong market demand in specific areas, suggesting potential for enhanced competitiveness through ongoing investment and innovation.
See More
Accendra Health (ACH) Q1 2026 Earnings Transcript
See More
Accendra Health Announces $1.5 Billion Balance Sheet Optimization
- Financial Optimization Transaction: Accendra Health has announced a comprehensive balance sheet optimization transaction exceeding $1.5 billion with existing creditors, aimed at strengthening its balance sheet, significantly extending maturities, and reducing leverage, thereby laying a solid foundation for the company's long-term growth.
- First Quarter Financial Results: For Q1 2026, net revenue was $627.8 million, down from $673.9 million year-over-year, although adjusted EBITDA stood at $58.4 million, indicating the company's ability to maintain profitability during its transformation into a home-based care provider.
- Liquidity Enhancement: This transaction will enable the company to pay off its 2027 maturities and extend its revolving credit facility, providing essential liquidity to support future strategic flexibility and ensuring a competitive edge in a challenging market.
- Investor Conference Call: Accendra Health will host an investor conference call on May 11, 2026, to discuss its first-quarter financial results, further enhancing communication with investors and boosting market confidence.
See More
Owens & Minor to Announce Q1 Earnings on May 11
- Earnings Announcement: Owens & Minor is set to release its Q1 2023 earnings report on May 11 before market open, with consensus EPS estimate at -$0.10 and revenue estimate at $644.64 million, reflecting the company's challenges and opportunities in the current economic landscape.
- Historical Performance Review: Over the past two years, Owens & Minor has beaten EPS estimates 88% of the time and revenue estimates 63% of the time, indicating a degree of stability in its financial performance despite market fluctuations.
- Estimate Revision Dynamics: In the last three months, there have been no upward revisions to EPS estimates and four downward revisions, while revenue estimates saw one upward revision and two downward revisions, suggesting a cautious market outlook on the company's future performance that may affect investor confidence.
- Market Focus: Investors will closely monitor the upcoming earnings report to assess Owens & Minor's adaptability in the current economic climate and its potential for future growth, especially amid increasing competition in the healthcare sector.
See More
Accendra Health Announces Early Results of Bond Exchange Offers
- Successful Bond Exchange Offers: As of June 9, 2026, Accendra Health received valid tenders for approximately $478.3 million of 2029 Notes and $547.9 million of 2030 Notes, representing 99.9% and 99.2% of the total amounts, respectively, indicating strong investor interest in the new bond issuance and enhancing the company's capital structure.
- New Bond Issuance Plan: The company plans to issue $326.25 million in aggregate principal amount of newly issued First Lien Notes, aimed at optimizing its financial condition through the introduction of new funds, which is expected to enhance the company's financial flexibility and market competitiveness.
- Amendment of Covenant Terms: The company has obtained the necessary consents from existing bondholders to amend covenant terms to eliminate most restrictive clauses, which will facilitate greater flexibility in future mergers and financing activities, further driving business growth.
- Timeline Adjustments: The expected early settlement date for all existing notes is set for June 15, 2026, with the expiration time for the exchange offers extended to June 23, 2026, providing investors with more opportunities to participate and potentially increasing the liquidity of the bonds.
See More
Accendra Health Launches Bond Exchange Offers
- Exchange Offer Initiation: Accendra Health has announced the commencement of exchange offers for its 4.500% and 6.625% Senior Notes, aiming to replace existing notes with newly issued 9.000% and 9.750% Senior Secured Notes, thereby optimizing its capital structure and reducing financing costs.
- New Money Notes Issuance: The company is offering $326.25 million in new money notes to incentivize existing noteholders to participate, which is expected to enhance liquidity and support future financial flexibility.
- Covenant Amendments: The company is soliciting significant amendments to the existing notes' covenants, including the elimination of most affirmative and negative covenants, which will help improve operational flexibility and reduce compliance costs.
- Commitment Agreement Support: The company has entered into a commitment agreement with existing noteholders, with approximately 83% of 2030 noteholders expected to participate, indicating strong market confidence in the company's strategic direction.
See More
Accendra Health Earnings Review: Revenue Decline and Debt Management
- Revenue Decline: Accendra Health reported a 6.8% revenue decline in Q1, primarily due to exiting a large commercial payor, with an estimated growth of about 1% if this impact is excluded, posing challenges to the company's future revenue stability.
- Adjusted EBITDA: The company achieved an adjusted EBITDA of $58 million, in line with expectations, indicating a relative stability in operational efficiency despite revenue pressures, reflecting its ability to maintain profitability.
- Debt Management Plan: The company anticipates deleveraging up to $115 million through exchange offers for new notes, although it faces an estimated annual interest expense increase of about $40 million, which will negatively impact free cash flow.
- Market Performance: Despite overall revenue decline, the sleep category achieved over 4% growth, indicating strong market demand in specific areas, suggesting potential for enhanced competitiveness through ongoing investment and innovation.
See More
Accendra Health (ACH) Q1 2026 Earnings Transcript
See More
Accendra Health Announces $1.5 Billion Balance Sheet Optimization
- Financial Optimization Transaction: Accendra Health has announced a comprehensive balance sheet optimization transaction exceeding $1.5 billion with existing creditors, aimed at strengthening its balance sheet, significantly extending maturities, and reducing leverage, thereby laying a solid foundation for the company's long-term growth.
- First Quarter Financial Results: For Q1 2026, net revenue was $627.8 million, down from $673.9 million year-over-year, although adjusted EBITDA stood at $58.4 million, indicating the company's ability to maintain profitability during its transformation into a home-based care provider.
- Liquidity Enhancement: This transaction will enable the company to pay off its 2027 maturities and extend its revolving credit facility, providing essential liquidity to support future strategic flexibility and ensuring a competitive edge in a challenging market.
- Investor Conference Call: Accendra Health will host an investor conference call on May 11, 2026, to discuss its first-quarter financial results, further enhancing communication with investors and boosting market confidence.
See More
Owens & Minor to Announce Q1 Earnings on May 11
- Earnings Announcement: Owens & Minor is set to release its Q1 2023 earnings report on May 11 before market open, with consensus EPS estimate at -$0.10 and revenue estimate at $644.64 million, reflecting the company's challenges and opportunities in the current economic landscape.
- Historical Performance Review: Over the past two years, Owens & Minor has beaten EPS estimates 88% of the time and revenue estimates 63% of the time, indicating a degree of stability in its financial performance despite market fluctuations.
- Estimate Revision Dynamics: In the last three months, there have been no upward revisions to EPS estimates and four downward revisions, while revenue estimates saw one upward revision and two downward revisions, suggesting a cautious market outlook on the company's future performance that may affect investor confidence.
- Market Focus: Investors will closely monitor the upcoming earnings report to assess Owens & Minor's adaptability in the current economic climate and its potential for future growth, especially amid increasing competition in the healthcare sector.
See More
